Ana Cristina Sousa Gramoza Vilarinho Santana

Ana Cristina Sousa Gramoza Vilarinho Santana

Auto-generated profile, based on publicly available information

Ana Cristina Sousa Gramoza Vilarinho Santana

Laboratory of Technological Innovation, Entrepreneurship, Medicines and Related (LITE), Nucleus of Pharmaceutical Technology, Federal University of Piauí, Teresina 64049-550, PI, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ILIzabela Lima
Izabela Lima
LMLina Clara G. A. I. Moreno
Lina Clara G. A. I. Moreno
APAna Victória Peres
Ana Victória Peres
ASAna Cristina Gramoza Santana
Ana Cristina Gramoza Santana
ACAdonias Carvalho
Adonias Carvalho
LNLivio Nunes
Livio Nunes
We encapsulated MSZ in zein nanoparticles (NP-ZN) using a desolvation method followed by drying in a mini spray dryer. These nanoparticles exhibited a size of 266.6 ± 52 nm, IPD of 0.14 ± 1.1 and zeta potential of −36.4 ± 1.5 mV, suggesting colloidal stability. Quantification using HPLC showed a drug-loaded of 43.8 µg/mg. SEM demonstrated a spherical morphology with a size variation from 220 to 400 nm. A FTIR analysis did not show drug spectra in the NPs in relation to the physical mixture, which suggests drug encapsulation without changing its chemical structure. A TGA analysis showed thermal stability up to 300 °C. In vitro release studies demonstrated gastroresistance and a sustained drug release at pH 7.4 (97.67 ± 0.32%) in 120 h. The kinetic model used for the release of MSZ from the NP-ZN in a pH 1.2 medium was the Fickian diffusion, in a pH 6.8 medium it was the Peppas–Sahlin model with the polymeric relaxation mechanism and in a pH 7.4 medium it was the Korsmeyer–Peppas model with the Fickian release mechanism, or “Case I”. An in vitro cytotoxicity study in the CT26.WT cell line showed no basal cytotoxicity up to 500 μg/mL. The NP-ZN showed to be a promising vector for the sustained release of MSZ in the colon by oral route.

29 November 2018 in Journal of Chromatographic Science
Verified
Journal Article
Closed access
ASAna Cristina Sousa Gramoza Vilarinho Santana
Ana Cristina Sousa Gramoza Vilarinho Santana
LDLucas Danda
Lucas Danda
LNLivio Cesar Cunha Nunes
Livio Cesar Cunha Nunes
JSJose Lamartine Soares Sobrinho
Jose Lamartine Soares Sobrinho
To develop an analytical method to simultaneous quantification of benznidazole (BNZ) and posaconazole (POS) by high-performance liquid chromatography with diode-array detection (HPLC-DAD) using design of experiments. Percentages of organic phase, buffer pH and flow rates of mobile phase were selected as independent variables by full factorial design (33), totaling 27 experiments. Significant factors were evaluated using factorial analysis of variance with 95% confidence level. Method optimization was performed using desirability profiles, considering BNZ/POS chromatographic resolution and peak areas. Further, the method was evaluated regarding its suitability and properly validated according to the international compendiums using the parameters: specificity, linearity, accuracy, precision, limit of detection and limit of quantification. The optimized method was achieved using Discovery® C8 column (250 mm × 4.6 mm; 5 μm particle size), methanol/acetate buffer (pH 3.5)(71:29) and detection at 260 nm. Retention times were 3.6 and 7.6 min for BNZ and POS, respectively, with good suitability of system and it was specific and linear (r2 >0.99) for both drugs, proving the efficiency of the method even in the presence of degradation products of POS. This new method is a great alternative to perform reliable, faster and cheaper analysis since the simultaneous quantification of the association BZN/POS is not reported yet in the literature.

29 April 2023
Verified
Book Chapter
Open access
CLCarliane Azevedo Santos Lima
Carliane Azevedo Santos Lima
FAFrancilda da Silva e Silva Abreu
Francilda da Silva e Silva Abreu
ASAna Cristina Sousa Gramoza Vilarinho Santana
Ana Cristina Sousa Gramoza Vilarinho Santana
Organizado por: Prof.ª Dr.ª Gabriela Eyng Possolli ISBN 978-65-5379-225-8 DOI: 10.47573/aya.5379.2.174 N° páginas: 300 Formato: Livro Digital (PDF)

2 June 2025 in Revista Contemporânea
Verified
Journal Article
Open access
PDF file
HNHendreane Ferreira Nunes
Hendreane Ferreira Nunes
CMCícera Vandeyse Barbosa de Melo
Cícera Vandeyse Barbosa de Melo
ASAna Cristina Sousa Gramoza Vilarinho Santana
Ana Cristina Sousa Gramoza Vilarinho Santana
O uso medicinal de canabinoides, em especial o canabidiol (CBD), tem atraído interesse crescente devido à sua ampla aplicabilidade em alimentos funcionais, cosméticos e tratamentos médicos. Recentemente, o CBD destacou-se como uma possível terapia complementar para diversas condições de saúde, incluindo o diabetes mellitus tipo 2 (DM2). O objetivo geral deste trabalho foi avaliar os efeitos do CBD no tratamento do DM2. Tratou-se de uma revisão integrativa, conduzida nas bases de dados PubMed, Scielo e Embase, utilizando critérios rigorosos de inclusão e exclusão. A partir da estratégia de busca, foram encontrados inicialmente um total de 124 artigos completos, os quais foram triados e avaliados, contemplando uma amostra final de 10 estudos incluídos na revisão. Verificou-se que a maioria dos estudos realizados e incluídos são do tipo experimental, que utilizaram ratos machos. A dosagem de canabidiol utilizada variou de 0,5 a 100mg/dia. Os estudos analisados revelam resultados promissores, especialmente quanto à redução da glicemia, melhora da sensibilidade à insulina e regulação de parâmetros inflamatórios e lipídicos, ainda que os efeitos variem conforme o modelo experimental, a dose utilizada e a formulação administrada. Dessa forma, conclui-se que o CBD apresenta potencial terapêutico relevante como adjuvante no controle do DM2, especialmente por seus efeitos anti-inflamatórios, hipoglicemiantes e moduladores do metabolismo lipídico, sendo necessário, contudo, o avanço de estudos clínicos controlados para consolidar sua eficácia e segurança em humanos.